Nobel Biocare Releases Groundbreaking Edentulous Solution, Trefoil™, in Canada

At the 2018 Pacific Dental Conference, taking place in Vancouver, Canada, March 8th and 9th, Nobel Biocare is launching the Trefoil system into the Canadian market for dental implant solutions. It is the latest addition to the company’s proven assortment of groundbreaking full-arch solutions for patients in most need.

The Trefoil system represents a breakthrough in efficiency for treating edentulous patients and patients with failing dentition, enabling the fixed, definitive, full-arch restoration of the mandible in one day*. These significant efficiency gains are the result of an optimized workflow and componentry, which enable shorter time-to-teeth and reduced chair time in comparison with conventional treatments that require provisional restorations.

The cost-effective Trefoil system features a pre-manufactured titanium bar. Passive fit is made possible by a groundbreaking fixation mechanism that compensates for deviations in implant placement. The bar is retained on three implants featuring the TiUnite surface, which is proven to support Immediate Function.1 Combined with the straightforward restorative workflow, this makes the delivery of a fixed, definitive, full-arch restoration possible on the day of surgery*.

One-year clinical data already available
The Trefoil system is already backed by a year of scientific evidence showing successful early clinical outcomes. A poster presented at the EAO Annual Congress in 2017 highlighted the one-year results of a five-year multicenter clinical study evaluating the Trefoil system at five sites across four continents.2 The preliminary findings of the five-year multicenter clinical study show high implant and prosthetic survival rates, minor marginal bone remodeling and short time-to-teeth. Patients and clinicians reported excellent functional and esthetic satisfaction at all follow-up assessments, with patients also experiencing notable improvements in quality of life following restoration.

The Trefoil system is the latest addition to the extensive range of edentulous treatment solutions pioneered by Nobel Biocare. It joins the All-on-4® treatment concept as well as the NobelZygoma implant system for the treatment of the severely resorbed maxilla and the extended line of NobelSpeedy implants.

Hans Geiselhöringer, President, Nobel Biocare said: “Nobel Biocare is the undisputed forerunner in full-arch restorations and the launch of the Trefoil system consolidates our leading position in the treatment of patients for whom the potential improvement in quality of life is greatest. The Trefoil system is designed to make a high-quality fixed solution a reality for more of those in need, exemplifying our goal of helping our customers treat more patients better. It is an excellent addition to our already unrivaled range of edentulous solutions.”

*Depending on the preference of the clinician and close cooperation with the laboratory


  1. Degidi M, Nardi D, Piattelli A. 10-year follow-up of immediately loaded implants with tiunite porous anodized surface. Clin Implant Dent Relat Res 2012;14(6):828-838.
  2. Higuchi K, Davó R, Liddelow G, et al. An adaptive prefabricated full-arch framework on three implants in the mandible: preliminary results. Poster presented at: 26th Annual Scientific Meeting of the European Association for Osseointegration; Oct. 5–7, 2017; Madrid, Spain.

About Nobel Biocare
Nobel Biocare is a world leader in the field of innovative implant-based dental restorations. The company’s portfolio offers solutions from single tooth to fully edentulous indications with dental implant systems (including key brands NobelActive®, NobelParallel®, Brånemark System® and NobelReplace®), a comprehensive range of high-precision individualized prosthetics and CAD/CAM systems (NobelProcera®), treatment planning and guided surgery solutions (NobelClinician® and NobelGuide®) and biomaterials (creos). Nobel Biocare supports its customers through all phases of professional development, offering world-class training and education along with practice support and patient information materials. The company is headquartered in Zurich, Switzerland. Production takes place at five sites located in the United States, Sweden, Japan and Israel. Products and services are available in over 80 countries through subsidiaries and distributors.